Group 1 - On September 2, 2023, Huida Technology had a financing buy-in of 1.08 billion yuan and a financing repayment of 1.05 billion yuan, resulting in a net financing buy of 3.3754 million yuan [2] - On August 25, 2023, Huida Technology announced that its president, Liu Yuping, received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected insider trading, which may allow affected investors to seek compensation [3] - The CSRC's investigation is based on the Securities Law and Administrative Penalty Law of the People's Republic of China, indicating potential legal implications for the company and its executives [3] Group 2 - On August 1, 2023, Huida Technology announced the conditions for the second exercise period of its stock option incentive plan, which allows for the exercise of 403.65 million stock options at a price of 55.38 yuan per option [4] - The second exercise period is set from August 25, 2025, to August 24, 2026, with a total of 944 individuals eligible to exercise their options [4] - The law firm Guohao (Shenzhen) has confirmed that the exercise matters have received the necessary approvals and comply with relevant regulations [4] Group 3 - Huida Technology has participated in 28 bidding projects and holds 81 trademark registrations, indicating its active engagement in business development and intellectual property management [5]

Group 1 - The core point of the article is that 聚石化学 (Jushi Chemical) has approved a stock option incentive plan for its employees, granting 1,200,000 stock options to 18 individuals as part of its strategy to motivate and retain talent [1] Group 2 - The stock option grant is part of the company's seventh board of directors' compensation and assessment committee meeting, which took place on September 3, 2025 [1] - The board believes that the conditions for granting the reserved stock options have been met, and the authorization date for this grant is set for September 3, 2025 [1]

证券代码：688669 证券简称：聚石化学 公告编号：2025-055 广东聚石化学股份有限公司 关于向2025 年股票期权激励计划激励对象授予预留部分 股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股票期权预留授权日：2025 年 9 月 3 日 股票期权预留授予数量：1,200,000 份，占目前公司股本总额的0.99% 股权激励方式：股票期权 《广东聚石化学股份有限公司 2025 年股票期权激励计划（草案）》（以下 简称"《激励计划（草案）》"、"本激励计划"）规定的股票期权预留授予条 件已经成就，根据广东聚石化学股份有限公司（以下简称"公司"）2025 年第一次 临时股东大会的授权，公司于 2025 年 9 月 3 日召开第七届董事会第四次会议，审 议通过了《关于向 2025 年股票期权激励计划激励对象授予预留部分股票期权的议 案》，确定股票期权的预留授权日为 2025 年 9 月 3 日，现将有关事项说明如下。 一、股票期权授予情况 （一）已履行的相关审批程序和信息披露情况 《关 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of the stock option incentive plan for 2024 by Keli Electric Motor Group Co., Ltd, which aims to attract and retain talent while aligning employee interests with those of shareholders [1][12]. Group 1: Incentive Plan Overview - The incentive plan involves a total of 4.01 million stock options, representing 0.65% of the company's total share capital, with 3.21 million options for initial grants (80% of total) and 802,500 options reserved for future grants (20%) [1][2]. - The plan's effective period lasts up to 60 months from the completion of the initial grant registration [2]. Group 2: Grant and Vesting Details - The initial grant date will be determined by the board within 60 days after shareholder approval, and the reserved options must be granted within 12 months post-approval [2][3]. - The waiting periods for the initial grants are set at 12, 24, and 36 months, while the reserved grants have similar waiting periods [2][3]. Group 3: Exercise Conditions - The exercise of stock options is contingent upon meeting specific performance targets, including a positive net profit for the corresponding assessment years [5][6]. - The performance targets for the first exercise period require a minimum revenue of 1.425 billion yuan for 2024, with cumulative targets for subsequent years [6][7]. Group 4: Approval Process - The plan has undergone necessary approvals, including reviews by the board and supervisory committee, with no objections raised during the public notice period [7][9]. - The stock options were officially registered on September 3, 2025, with a grant date of August 25, 2025, and an exercise price set at 5.43 yuan per share [10][11]. Group 5: Impact on Company - The implementation of this incentive plan is expected to enhance the company's ability to attract and retain talent, thereby strengthening its competitive advantage in the market [12].

Core Points - The company has completed the cancellation of 524,300 stock options from the 2021 stock option incentive plan due to certain performance criteria not being met by some incentive recipients [2][3] - The cancellation was approved by the board of directors and aligns with the regulations set forth in the "Management Measures for Equity Incentives of Listed Companies" and the company's own incentive plan [3] - The cancellation will not significantly impact the company's financial status or operational results, nor will it affect the motivation and stability of the management team [3] Summary by Sections - **Announcement of Cancellation**: The company announced the cancellation of stock options for 31 incentive recipients who did not fully meet the performance assessment for 2024, resulting in a total of 524,300 options being canceled [2] - **Regulatory Compliance**: The cancellation process has been submitted to and confirmed by the Shenzhen branch of China Securities Depository and Clearing Co., Ltd., ensuring compliance with relevant regulations [3] - **Impact Assessment**: The company asserts that this cancellation will not disrupt the ongoing 2021 stock option incentive plan and emphasizes the management team's commitment to creating value for shareholders [3]

Core Viewpoint - Shenzhen Laisai Intelligent Control Co., Ltd. has made adjustments to its stock incentive plans, including changes to the repurchase price of restricted stock and the exercise price of stock options, as well as the conditions for lifting restrictions on certain stock grants [1][3][6] Summary by Sections Adjustment of Stock Incentive Plans - The board approved adjustments to the repurchase price of restricted stock from 7.54 CNY/share to 7.22 CNY/share and the exercise price of stock options from 19.95 CNY/share to 19.63 CNY/share [1][3] Lifting of Restrictions on Stock Grants - The board confirmed that the conditions for lifting restrictions on the third phase of the initial grant of the 2022 restricted stock incentive plan and the second phase of the reserved grant have been met, allowing 81 beneficiaries to lift restrictions on 2,768,000 shares, which represents 0.88% of the company's total share capital [1][5] Repurchase and Cancellation of Restricted Stock - The board proposed to repurchase and cancel restricted stock for 86 beneficiaries who have either left or are about to leave the company, involving 832,000 shares that have been granted but not yet had restrictions lifted. The repurchase price will include the grant price plus interest from bank deposits [1][6]

Core Points - The company held the 16th meeting of the 5th Supervisory Board on September 2, 2025, where several resolutions were passed regarding the stock incentive plans [1][2][3] Group 1: Adjustments to Stock Incentive Plans - The Supervisory Board approved the adjustment of the repurchase price for the 2022 restricted stock incentive plan and the exercise price for the 2022 stock option incentive plan, confirming that these adjustments do not harm the interests of shareholders [1][2] - The board unanimously agreed to the proposal with a vote of 3 in favor, 0 against, and 0 abstentions [2][3] Group 2: Release of Restrictions on Stock Incentives - The board approved the release of restrictions on the third phase of the initial grant of the 2022 restricted stock incentive plan and the second phase of the reserved grant, confirming that the conditions for lifting restrictions have been met by the eligible participants [2][3] - A total of 81 eligible participants will have their restrictions lifted as per the regulations [2][3] Group 3: Repurchase and Cancellation of Restricted Stocks - The board approved the repurchase and cancellation of restricted stocks from 86 incentive participants who have either left or are about to leave the company, or have not fully met the performance criteria [3][4] - The total number of restricted stocks involved in this repurchase is 832,000 shares, with the repurchase price being the grant price plus the interest from bank deposits [3][4]

广东华商律师事务所 关于 深圳市雷赛智能控制股份有限公司 调整 2022 年限制性股票激励计划回购价格、2022 年 股票期权激励计划行权价格 的 法律意见书 二〇二五年九月 深圳市福田区深南大道 4011 号香港中旅大厦 21-26 层 电话(Tel)：0086-755-83025555 传真(Fax)：0086-755-83025068 邮政编码(P.C.)：518000 网址 http://www.huashang.cn 法律意见书 广东华商律师事务所 关于深圳市雷赛智能控制股份有限公司 调整 2022 年限制性股票激励计划回购价格、2022 年股票期 权激励计划行权价格的 法律意见书 致：深圳市雷赛智能控制股份有限公司 广东华商律师事务所（以下简称"本所"）接受深圳市雷赛智能控制股份有 限公司（以下简称"公司"或"雷赛智能"）的委托，作为公司实施 2022 年股 票期权激励计划及 2022 年限制性股票计划（以下合称"激励计划"）的特聘专项 法律顾问。现根据《中华人民共和国公司法》 （以下简称" 《公司法》"）、 《中华人 民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办法》 ...

Core Viewpoint - Junshi Biosciences (01877) announced the approval of the 2025 H-share and A-share stock option incentive plans by the board of directors, which require shareholder approval due to the issuance of new shares [1] Group 1: Stock Option Incentive Plans - The board has approved the proposal to adopt the 2025 H-share stock option incentive plan and the 2025 A-share stock option incentive plan [1] - The 2025 H-share stock option incentive plan includes the granting of 13.21 million H-share stock options to seven executive directors and three other employee participants [1] - The 2025 A-share stock option incentive plan proposes granting 8 million A-share stock options to Mr. Xiong, contingent upon the adoption of the respective plans [1]

格隆汇9月2日丨君实生物(01877.HK)公告，于2025年9月2日，董事会已审议及批准(其中包括)(i)建议采 纳2025年H股股票期权激励计划；及(ii)采纳2025年A股股票期权激励计划。根据上市规则第十七章， 2025年H股股票期权激励计划及2025年A股股票期权激励计划将构成公司涉及发行新股份的股份计划， 因此采纳2025年H股股票期权激励计划及2025年A股股票期权激励计划须获股东批准。 ...